Global Insight Services have recently published a report on Dysmenorrhea – Drug Pipeline Landscape. The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration.
Dysmenorrhea, also known as painful periods or menstrual cramps, is a common problem experienced by women during their reproductive years. It is estimated that 50-90% of women of reproductive age suffer from dysmenorrhea. The pain is usually felt in the lower abdomen and can range from mild to severe. The pain may begin one to two days before the start of menstruation and last for the first few days of bleeding.
There are two types of dysmenorrhea: primary and secondary. Primary dysmenorrhea is the most common type and is characterized by pain that starts around the time of menstruation and is not associated with any other underlying medical condition. Secondary dysmenorrhea is less common and is caused by an underlying medical condition such as endometriosis, pelvic inflammatory disease, or fibroids.
Request for a PDF sample copy of report: https://www.globalinsightservices.com/request-sample/GIS31122
Global Insight Service’s, Dysmenorrhea – Drug Pipeline Landscape, 2022 report provides an overview of the Dysmenorrhea pipeline drugs. This report covers detailed insights on Dysmenorrhea drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Dysmenorrhea pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Some of the key players involved in development of Dysmenorrhea therapeutics are :
- Fuji Pharma Japan Inc
- Latitude Pharmaceuticals Inc
- Myovant Sciences GmbH
- ObsEva SA
- PNB Vesper Life Sciences
Buy this report: https://www.globalinsightservices.com/checkout/single_user/GIS31122
With Global Insight Services, you receive:
- 10-year forecast to help you make strategic decisions
• In-depth segmentation which can be customized as per your requirements
• Free consultation with lead analyst of the report
• Excel data pack included with all report purchases
• Robust and transparent research methodology
About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.
This Press Release has been written with the intention of providing accurate market information which will enable our readers to make informed strategic investment decisions. If you notice any problem with this content, please feel free to reach us on [email protected]